Anebulo Pharmaceuticals, Inc. (ANEB)

3.4800 +0.2100 (+6.42%) At close: 03:58PM EDT

Anebulo Pharmaceuticals, Inc.

1415 Ranch Road 620 South
Suite 201
Lakeway, TX 78734
United States
512-598-0931
https://www.anebulo.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Joseph F. Lawler M.D., Ph.D.	Founder & Chairman	11k	N/A	1972
Mr. Simon J. Allen B.Sc., M.B.A., MBA	CEO & Director	450k	N/A	1968
Dr. Kenneth C. Cundy Ph.D.	Chief Scientific Officer	345.53k	N/A	1959
Mr. Scott L. Anderson	Head of Investor Relations & Public Affairs	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. The company was incorporated in 2020 and is based in Lakeway, Texas.

Corporate Governance

Anebulo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.